{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:06:37Z","timestamp":1794017197185,"version":"4.8.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73085-1","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:06:12Z","timestamp":1778893572000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5989-6636","authenticated-orcid":false,"given":"Ana C.","family":"Garrido-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jett","family":"Crowdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-1995","authenticated-orcid":false,"given":"Yvonne","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hersh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Petry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5461-9777","authenticated-orcid":false,"given":"Lincoln W.","family":"Pasquina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashka","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"DiLullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Attaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mae","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-784X","authenticated-orcid":false,"given":"Merrida A.","family":"Childress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Faggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline C.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Toke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-1206","authenticated-orcid":false,"given":"Wendy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1829-302X","authenticated-orcid":false,"given":"Kai W.","family":"Wucherpfennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9655-7123","authenticated-orcid":false,"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satabhisa","family":"Mukhopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tathagata","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Schnitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Cherniack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0633-3151","authenticated-orcid":false,"given":"Jennifer","family":"Ligibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9762-8536","authenticated-orcid":false,"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6088-167X","authenticated-orcid":false,"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5940-8671","authenticated-orcid":false,"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"73085_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73085_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429\u20134434 (2007).","journal-title":"Clin. Cancer Res"},{"key":"73085_CR3","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1002\/cncr.27581","volume":"118","author":"NU Lin","year":"2012","unstructured":"Lin, N. U. et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118, 5463\u20135472 (2012).","journal-title":"Cancer"},{"key":"73085_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 9, 176\u2013198 (2019).","journal-title":"Cancer Discov."},{"key":"73085_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"73085_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","volume":"32","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann. Oncol. 32, 983\u2013993 (2021).","journal-title":"Ann. Oncol."},{"key":"73085_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396, 1817\u20131828 (2020).","journal-title":"Lancet"},{"key":"73085_CR8","unstructured":"Rugo, H. S. et al. in ESMO Congress. (2025)."},{"key":"73085_CR9","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","volume":"33","author":"SJ Isakoff","year":"2015","unstructured":"Isakoff, S. J. et al. TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J. Clin. Oncol. 33, 1902\u20131909 (2015).","journal-title":"J. Clin. Oncol."},{"key":"73085_CR10","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt, A. et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24, 628\u2013637 (2018).","journal-title":"Nat. Med."},{"key":"73085_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci, L., Schiavoni, G., Sistigu, A. & Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 21, 15\u201325 (2014).","journal-title":"Cell Death Differ."},{"key":"73085_CR12","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","volume":"20","author":"SV Hato","year":"2014","unstructured":"Hato, S. V., Khong, A., de Vries, I. J. & Lesterhuis, W. J. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin. Cancer Res. 20, 2831\u20132837 (2014).","journal-title":"Clin. Cancer Res."},{"key":"73085_CR13","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR de Biasi","year":"2014","unstructured":"de Biasi, A. R., Villena-Vargas, J. & Adusumilli, P. S. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. 20, 5384\u20135391 (2014).","journal-title":"Clin. Cancer Res."},{"key":"73085_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk, L. et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920\u2013928 (2019).","journal-title":"Nat. Med."},{"key":"73085_CR15","doi-asserted-by":"publisher","unstructured":"Vokes, N. I. et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis. Oncol. 3, https:\/\/doi.org\/10.1200\/po.19.00171 (2019).","DOI":"10.1200\/po.19.00171"},{"key":"73085_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","volume":"10","author":"BD Lehmann","year":"2024","unstructured":"Lehmann, B. D. et al. Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol. 10, 193\u2013201 (2024).","journal-title":"JAMA Oncol."},{"key":"73085_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2024.42.16_suppl.605","volume":"42","author":"N Tung","year":"2024","unstructured":"Tung, N. et al. Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in germline BRCA carriers with HER2-negative breast cancer (TBCRC 031) [abstract. J. Clin. Oncol. 42, 605 (2024).","journal-title":"J. Clin. Oncol."},{"key":"73085_CR18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles, D. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Ann. Oncol. 32, 994\u20131004 (2021).","journal-title":"Ann. Oncol."},{"key":"73085_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent, R. et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann. Oncol. 35, 630\u2013642 (2024).","journal-title":"Ann. Oncol."},{"key":"73085_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"73085_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens, L. A. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 study. J. Natl. Cancer Inst. 113, 1005\u20131016 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"73085_CR22","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1158\/1078-0432.CCR-19-3507","volume":"26","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa, R. et al. Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1\/L1 blockade in metastatic triple-negative breast cancer. Clin. Cancer Res. 26, 2565\u20132572 (2020).","journal-title":"Clin. Cancer Res."},{"key":"73085_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00413","volume":"6","author":"R Barroso-Sousa","year":"2022","unstructured":"Barroso-Sousa, R. et al. Multidimensional molecular profiling of metastatic triple-negative breast cancer and immune checkpoint inhibitor benefit. JCO Precis Oncol. 6, e2100413 (2022).","journal-title":"JCO Precis Oncol."},{"key":"73085_CR24","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"73085_CR25","doi-asserted-by":"publisher","first-page":"e2431722","DOI":"10.1001\/jamanetworkopen.2024.31722","volume":"7","author":"K Dickinson","year":"2024","unstructured":"Dickinson, K. et al. Circulating tumor DNA and survival in metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw. Open 7, e2431722 (2024).","journal-title":"JAMA Netw. Open"},{"key":"73085_CR26","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-22-3769","volume":"29","author":"SB Maron","year":"2023","unstructured":"Maron, S. B. et al. Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer. Clin. Cancer Res. 29, 3633\u20133640 (2023).","journal-title":"Clin. Cancer Res."},{"key":"73085_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamaoncol.2020.7310","volume":"7","author":"OM Filho","year":"2021","unstructured":"Filho, O. M. et al. Association of immunophenotype with pathologic complete response to neoadjuvant chemotherapy for triple-negative breast cancer: a secondary analysis of the brighTNess phase 3 randomized clinical trial. JAMA Oncol. 7, 603\u2013608 (2021).","journal-title":"JAMA Oncol."},{"key":"73085_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s10549-013-2579-x","volume":"139","author":"J Bjohle","year":"2013","unstructured":"Bjohle, J. et al. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res. Treat. 139, 751\u2013758 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"73085_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61416-1","volume":"10","author":"AM Larsson","year":"2020","unstructured":"Larsson, A. M. et al. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Sci. Rep. 10, 4484 (2020).","journal-title":"Sci. Rep."},{"key":"73085_CR30","doi-asserted-by":"crossref","unstructured":"Costa Svedman, F. et al. Plasma thymidine kinase activity as a novel biomarker in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancers 14, 702 (2022).","DOI":"10.3390\/cancers14030702"},{"key":"73085_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"73085_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41591-022-01698-2","volume":"28","author":"JA McCulloch","year":"2022","unstructured":"McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545\u2013556 (2022).","journal-title":"Nat. Med."},{"key":"73085_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"73085_CR34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cmet.2023.03.003","volume":"35","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis. Cell Metab. 35, 651\u2013666 e657 (2023).","journal-title":"Cell Metab."},{"key":"73085_CR35","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.cell.2018.07.019","volume":"174","author":"JS Lee","year":"2018","unstructured":"Lee, J. S. et al. Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures. Cell 174, 1559\u20131570 (2018).","journal-title":"Cell"},{"key":"73085_CR36","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"73085_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"73085_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"73085_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia, E. P. et al. Validation of OncoPanel: A targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch. Pathol. Lab Med. 141, 751\u2013758 (2017).","journal-title":"Arch. Pathol. Lab Med."},{"key":"73085_CR40","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jmoldx.2014.06.004","volume":"16","author":"LE MacConaill","year":"2014","unstructured":"MacConaill, L. E. et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J. Mol. Diagn. 16, 660\u2013672 (2014).","journal-title":"J. Mol. Diagn."},{"key":"73085_CR41","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1158\/1078-0432.CCR-20-1720","volume":"27","author":"AC Garrido-Castro","year":"2021","unstructured":"Garrido-Castro, A. C. et al. Genomic Characterization of de novo Metastatic Breast Cancer. Clin. Cancer Res. 27, 1105\u20131118 (2021).","journal-title":"Clin. Cancer Res."},{"key":"73085_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"YHY Benjamini","year":"1995","unstructured":"Benjamini, Y. H. Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"73085_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"73085_CR44","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73085_CR45","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 11, e0157368 (2016).","journal-title":"PLoS ONE"},{"key":"73085_CR46","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","volume":"30","author":"CJ Sweeney","year":"2024","unstructured":"Sweeney, C. J. et al. Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 30, 4115\u20134122 (2024).","journal-title":"Clin. Cancer Res."},{"key":"73085_CR47","doi-asserted-by":"publisher","unstructured":"Brown, D. W. et al. Abstract 1959: Variant Origin Prediction (VOP) determines the tumor-somatic, germline, or clonal hematopoiesis (CH) origin of short variants (SVs) detected in liquid biopsy (LBx). Cancer Res. 85, https:\/\/doi.org\/10.1158\/1538-7445.AM2025-1959 (2025).","DOI":"10.1158\/1538-7445.AM2025-1959"},{"key":"73085_CR48","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/oncolo\/oyae149","volume":"29","author":"DC Pavlick","year":"2024","unstructured":"Pavlick, D. C., Frampton, G. M. & Ross, J. R. Understanding variants of unknown significance and classification of genomic alterations. Oncologist 29, 658\u2013666 (2024).","journal-title":"Oncologist"},{"key":"73085_CR49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1198\/106186006X133933","volume":"15","author":"T Hothorn","year":"2006","unstructured":"Hothorn, T., Hornik, K. & Zeileis, A. Unbiased Recursive Partitioning: A Conditional Inference Framework. J. Comput. Graph. Stat. 15, 651\u2013674 (2006).","journal-title":"J. Comput. Graph. Stat."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73085-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73085-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73085-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:02:32Z","timestamp":1784289752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73085-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73085"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73085-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C.G.-C. reports research funding (to Institution) from AstraZeneca, Bicycle Therapeutics, Biovica, BioNTech, Bristol-Myers Squibb, Case45, Daiichi Sankyo, Foundation Medicine, Gilead Sciences, Merck & Co., Novartis, Precede Biosciences, Reveal Genomics, Zenith Epigenetics, 4D Path; compensated service for consulting and service on scientific advisory boards and\/or steering committee for AstraZeneca, BioNTech, Bristol-Myers Squibb, Daiichi Sankyo, Gilead Sciences, Merck & Co., Novartis, TD Cowen, and Pfizer; speaker honoraria from AstraZeneca, Daiichi Sankyo, Gilead Sciences, Bicycle Therapeutics, and Roche\/Genentech; travel\/other financial support from Roche\/Genentech, Gilead Sciences, AstraZeneca, Daiichi Sankyo, Merck & Co., Novartis, Stemline Therapeutics, and Pfizer. S.M.T. reports consulting or advisory roles at Novartis, Pfizer\/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech\/Roche, Eisai, Bristol Myers Squibb\/Systimmune, Daiichi Sankyo, Gilead, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Artios Pharma, Menarini\/Stemline, Aadi Bio, Bayer, Jazz Pharmaceuticals, Natera, Tango Therapeutics, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech, Launch Therapeutics, Zuellig Pharma, Johnson&Johnson\/Ambrx, Bicycle Therapeutics, BeiGene Therapeutics, Mersana, Summit Therapeutics, Avenzo Therapeutics, Aktis Oncology, Celcuity, Boehringer Ingelheim, Samsung Bioepis, Olema Pharmaceuticals, Tempus, Boundless Bio, Denali Therapeutics, Relay Therapeutics; research funding (to Institution) from Genentech\/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, AstraZeneca, NanoString Technologies, Gilead, SeaGen, OncoPep, Daiichi Sankyo, Menarini\/Stemline, Jazz Pharmaceuticals, Olema Pharmaceuticals; and travel support from Eli Lilly, Gilead, Jazz Pharmaceuticals, Pfizer, Arvinas, Roche. K.W.W. serves on the scientific advisory boards of DEM BioPharma, Solu Therapeutics, D2M Biotherapeutics, DoriNano, Inc., and Nextechinvest. He is a co-founder of Immunitas Therapeutics and receives sponsored research funding from Fate Therapeutics. He holds equity in TScan Therapeutics. These activities are not related to the research reported in this publication. A.D.C. reports he receives research funding from Bayer and consults for KaryoVerse. E.M.V. reports advisory\/consulting roles for Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, TracerBio; research support from Novartis, BMS, Sanofi, NextPoint; equity in Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse, TracerDx; speaking fees from TD Cowen; institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation; intermittent legal consulting on patents for Foaley & Hoag; and an editorial board role at Science Advances. N.U.L. reports institutional research support from Genentech, Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals (as part of Roche\/GNE), Olema Pharmaceuticals, AstraZeneca, Iksuda, Stemline, consulting honoraria from Pfizer\/SeaGen, Daiichi Sankyo, AstraZeneca, Olema Pharmaceuticals, Stemline\/Menarini, Artera Inc., Eisai, Shorla Oncology, Denali Therapeutics, royalties from UptoDate and travel support from Olema, AstraZeneca, Daiichi Sankyo. R.Pe., L.W.P., and M.A.C. are full-time employees of Foundation Medicine, Inc, and hold stock in Roche Holdings AG. S.M. and T.D. are employees at 4D Path. A.J.W. is an employee of Biovica Inc. All remaining authors report no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6490"}}